Search Results 611-620 of 4359 for 搜索留痕平台咨询邮箱：lgooxc@hotmail.com

1. A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Subjects With Select Advanced Malignancies - Mayo Clinic

   A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in ...

2. A Study of BBI608 in Combination With Sorafenib, or BBI503 in Combination With Sorafenib in Adult Patients With Hepatocellular Carcinoma - Mayo Clinic

   Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and ...

3. Faculty - Department of Quantitative Health Sciences - Mayo Clinic Research

   Expert faculty members guide research and education in Mayo Clinic's Department of Quantitative Health Sciences.

4. Contact - Translational Neuropathology Laboratory - Mayo Clinic Research

   Research Program Coordinator · Translational Neuropathology Laboratory · Mayo Clinic 4500 San Pablo Road Jacksonville, FL 32224 · Phone: 904-953-2575 · Email: ...

5. Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer - Mayo Clinic

   Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor ...

6. Biotinylated Vectors as Ligand Screening Platforms - Virology, Vector and Vaccine Engineering: Michael A. Barry - Mayo Clinic Research

   Learn about biotinylated vectors as ligand screening platforms in the Virology, Vector and Vaccine Engineering Laboratory of Michael A. Barry, Ph.D., ...

7. ORC-13661 for the Prevention of Drug-Induced Hearing Loss in Intravenous Amikacin Treatment of Non-Tuberculous Mycobacterium Disease - Mayo Clinic

   The purpoes of this study is to evaluate the safety of ORC-13661 and its ability to significantly mitigate or prevent hearing loss in patients being treated ...

8. Testing the Addition of a New Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Rituximab) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma - Mayo Clinic

   Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Rituximab is a monoclonal antibody that may interfere with ...

9. Multi-center Trial in Adult and Pediatric Patients With Type 1 Diabetes Using Hybrid Closed Loop System at Home - Mayo Clinic

   About this study. The purpose of this study is to demonstrate the safety and effectiveness of the Hybrid Closed Loop system (HCL) in adult and pediatric ...

10. Student Profiles - Training and Education - Center for Clinical and Translational Science (CCaTS)

    Mayo Clinic Center for Clinical and Translational Science (CCaTS): Profiles of students in the M.D.-M.S. Program.